NDC-1308

A NOVEL COVID-19 THERAPEUTIC

ANTI-INFLAMMATORY & ANTIVIRAL

“ENDECE is dedicated to the discovery and development of treatments that stop disease progression, restore function, and improve quality of life.”

Dr. James Yarger, Ph.D.

President

LATEST NEWS

ENDECE developed NDC-1308, a novel COVID-19 therapeutic designed to reduce inflammation in the lungs as well as the number of ACE2 receptors in the pulmonary system, reducing viral load. By reducing pulmonary inflammation and viral load, as well as preventing cytokine storm due to viral infections like SARS-CoV-2 / COVID-19, NDC-1308 should reduce long term effects, keep people off ventilators, and even prevent death.

NDC-1308 A NOVEL COVID-19 THERAPEUTIC

ANTI-INFLAMMATORY

ENDECE developed NDC-1308, a potential treatment for SARS-CoV-2, which has caused the current COVID-19 pandemic. NDC-1308 has the potential to reduce lung inflammation.

ANTIVIRAL

NDC-1308 may have the ability to reduce the number of ACE2 receptors in the pulmonary system, reducing viral load in SARS-CoV-2 / COVID-19 patients.